Advertisement
Advertisement
TPST
Tempest Therapeutics, Inc. Common Stock
1.18
USDSponsored
+0.14
+13.08%
Aug 11, 15:12 UTC -4
Open
TPST Earnings Reports
Positive Surprise Ratio
TPST beat 22 of 39 last estimates.
56%
Next Report
Date of Next Report
Nov 03, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$0.35
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q3 25 (Revenue/ EPS)
--
/-55.70%
Tempest Therapeutics, Inc. Common Stock earnings per share and revenue
On Aug 10, 2026, TPST reported earnings of -- USD per share (EPS) for Q2 26, -- the estimate of -0.30 USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference.
Looking ahead to Q3 26, -- analysts forecast an EPS of -0.35 USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Actinium Pharmaceuticals, Inc
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.22
Actual
$0.89
Surprise
+502.71%
Kiora Pharmaceuticals, Inc. Common Stock
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.63
Actual
-$0.34
Surprise
+46.24%
AIM ImmunoTech Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.17
Actual
-$0.43
Surprise
-150.44%
Oruka Therapeutics, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.52
Actual
-$0.55
Surprise
-4.62%
Harrow, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.34
Surprise
-85.19%
Silence Therapeutics Plc - ADR
Report Date
Aug 10, 2026 For Q2 26
Estimate
-Actual
-$0.26
Surprise
-
Nature's Sunshine Products Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.27
Actual
$0.21
Surprise
-23.75%
Minerva Neurosciences, Inc
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.11
Actual
-$0.17
Surprise
-44.93%
Tonix Pharmaceuticals Holding Corp.
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$2.75
Actual
-$2.44
Surprise
+11.29%
Fractyl Health, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.13
Actual
-$0.12
Surprise
+12.85%
FAQ
What were Tempest Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Tempest Therapeutics, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, 0% as expectations.
How did the market react to Tempest Therapeutics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Tempest Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 03, 2026.
What are the forecasts for Tempest Therapeutics, Inc. Common Stock's next earnings report?
Based on --
analysts, Tempest Therapeutics, Inc. Common Stock is expected to report EPS of -$0.35 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement